Payers

Five things for pharma marketers to know: Thursday, October 5, 2017

Five things for pharma marketers to know: Thursday, October 5, 2017

By

Cigna will no longer cover OxyContin; the AMA no longer supports price-fixing to lower drug prices; Gottlieb is not in favor of 'right-to-try' laws

Why use health plan apps? To search for specialists and understand drug coverage

Why use health plan apps? To search for specialists and understand drug coverage

By

Consumers younger than the age of 45 were most likely to use an app developed by their health plan.

Diabetes drugs must prove their value to payers, analysts say

Diabetes drugs must prove their value to payers, analysts say

By

CVS Health's decision to remove Lilly's Jardiance for J&J's Invokana has analysts wondering if exclusive pricing contracts could shape the future of the GLP-1 class.

Five things for pharma marketers to know: Tuesday, August 15, 2017

Five things for pharma marketers to know: Tuesday, August 15, 2017

By

Pfizer accuses J&J of limiting biosimilar uptake; Trump again criticizes high drug prices; WebMD to reposition site to help consumers manage their health

Biogen, Merck use predictive modeling to better negotiate value-based contracts

Biogen, Merck use predictive modeling to better negotiate value-based contracts

By

What's holding back value-based pricing deals from moving beyond the pilot phase?

Johnson & Johnson is big winner in CVS diabetes formulary changes

Johnson & Johnson is big winner in CVS diabetes formulary changes

By

CVS Health will remove Lilly's Jardiance in favor of J&J's Invokana.

Five things for pharma marketers to know: Tuesday, August 1, 2017

Five things for pharma marketers to know: Tuesday, August 1, 2017

By

Express Scripts removes 64 branded drugs from 2018 formulary; wearable market can regain momentum, analysts say; FDA accepts Herceptin biosimilars for review

Drugmakers face challenges marketing new heart drugs

Drugmakers face challenges marketing new heart drugs

By

Experts say this means drugmakers need to find new ways to communicate the value of their products.

Five things for pharma marketers to know: Friday, April 28, 2017

Five things for pharma marketers to know: Friday, April 28, 2017

By

Express Scripts-Anthem deal highlights profitability for PBMs; Sarepta CEO steps down; study says NHS cancer drug fund was ineffective

J&J blames lower Xarelto and Invokana sales on payer pressure

J&J blames lower Xarelto and Invokana sales on payer pressure

By

The drugmaker said it has been forced to provide higher rebates to PBMs and insurers for certain drugs.

Genentech urges broader adoption of value-based payment models

Genentech urges broader adoption of value-based payment models

By

A study published in Health Affairs detailed an outcomes-based pilot developed by the drugmaker and Priority Health, a Michigan-based health insurer.

Five things for pharma marketers to know: Thursday, February 23, 2017

Five things for pharma marketers to know: Thursday, February 23, 2017

By

Harvard Pilgrim signs pay-for-performance deals with Lilly and Amgen; new advocacy group wants lower drug prices; Zykadia gets priority review

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

By

Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.

Pharma/Payer Collaboration: A Kumbaya Moment or a Passing Trend?

Pharma/Payer Collaboration: A Kumbaya Moment or a Passing Trend?

By

The idea is that each gets some of what it needs. Payers gain some control over cost, and pharma may get to stay on formulary.

Merck and Aetna pair population health with risk-sharing, in two deals

Merck and Aetna pair population health with risk-sharing, in two deals

By

But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?

Infographic: What payers want from pharma

Infographic: What payers want from pharma

One pharmacy director would like to see a lot more comparative data about new therapies.

Five things for pharma marketers to know: Thursday, January 19, 2017

Five things for pharma marketers to know: Thursday, January 19, 2017

By

The FDA releases three documents; PBM rebates eating into drugmaker revenue: PhRMA; most oncologists on Twitter receive money from pharma

Pharma pushes to share off-label info with payers at FDA hearing

Pharma pushes to share off-label info with payers at FDA hearing

By

Insurers and pharmacy benefit managers already have a sophisticated understanding of clinical data, the industry argued.

The drug industry wins pricing battle in California, likely to fare better with Trump

The drug industry wins pricing battle in California, likely to fare better with Trump

By

But experts say that drug pricing will remain a significant issue for the industry going forward into a non-election year.

Best Multichannel Campaign (Large Product Size) of 2016

Best Multichannel Campaign (Large Product Size) of 2016

By

The Ways In campaign was UnitedHealthcare's first consumer advertising effort.

The Titanium Award: Best in Show in 2016

The Titanium Award: Best in Show in 2016

By

The multichannel effort — UnitedHealthcare's inaugural consumer brand advertising campaign — launched in March 2015 with the TV commercial Our Song.

Why Any Merger is the Last Resort of Lousy Marketers

Why Any Merger is the Last Resort of Lousy Marketers

By

Really? Is this the new healthcare math — the fewer the insurance companies, the greater the competition and the lower the premiums?

Five things for pharma marketers to know: Friday, September 9, 2016

Five things for pharma marketers to know: Friday, September 9, 2016

By

New Cigna campaign features TV doctors; Walgreens to divest 1,000 stores; senators question Aetna's health exchange exit

MM&M's top 5 stories in August 2016

MM&M's top 5 stories in August 2016

By

Shire hires Jennifer Aniston for a disease awareness campaign; critics argue that the direct-to-consumer ads for Opdivo are misleading, while Merck's Keytruda takes the lead in first-line cancer

Health exchanges, Obama administration challenged by recent insurer exits

Health exchanges, Obama administration challenged by recent insurer exits

By

The pull-back of insurance providers has left state-run health exchanges and the Obama administration facing a difficult communications challenge.

Five things for pharma marketers to know: Monday, August 29, 2016

Five things for pharma marketers to know: Monday, August 29, 2016

By

Mylan to launch generic EpiPen; the majority of NCCN guideline writers report conflicts of interest; Sanofi reports new trial data for Praluent

The co-pay card debate simmers, as payers push back

The co-pay card debate simmers, as payers push back

By

Will this payer pressure pose an existential threat to co-pay cards even though patients love them?

Lobbyists create off-label principles following FDA lawsuits

By

PhRMA and BIO, which represent life sciences firms, developed principles about sharing truthful and non-misleading information with payers and providers.

Five things for pharma marketers to know: Monday, August 15, 2016

Five things for pharma marketers to know: Monday, August 15, 2016

By

Express Scripts does not disclose names of formulary board members; Endo withdrew abuse-deterrent formulation for opioid; BI to collect real-world data on Praxbind

Analysts: Payers moving to address MS market as prices rise

Analysts: Payers moving to address MS market as prices rise

By

The impending payer crackdown of the cost of MS drugs could portend the fate of other specialty drug markets, according to analysts.